Patents Assigned to Chiron Corporation
  • Pyrazine based inhibitors of glycogen synthase kinase 3
    Publication number: 20060135534
    Abstract: New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Application
    Filed: August 10, 2005
    Publication date: June 22, 2006
    Applicant: Chiron Corporation
    Inventors: John Nuss, Savithri Ramurthy
  • Methods for isolating molecular mimetics of unique serogroup B epitopes
    Patent number: 7063949
    Abstract: Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: June 20, 2006
    Assignees: Chiron Corporation, Children's Hospital Medical Center of Northern California
    Inventors: Dan M. Granoff, Gregory R. Moe
  • Indazole benzimidazole compounds
    Patent number: 7064215
    Abstract: Organic compounds having the structure I are provided where the variables have the values described herein. Pharmaceutical formulations and medicaments include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compound or a pharmaceutically acceptable salt of the organic compound with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation or medicament according to the invention to a patient in need thereof.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: June 20, 2006
    Assignee: Chiron Corporation
    Inventors: Paul A. Renhowe, Cynthia M. Shafer, Christopher McBride, Joel Benjamin Silver, Sabina Pecchi, Timothy D. Machajewski, William R. McCrea, Jr., Daniel J. Poon, Teresa Thomas
  • Fluorogenic dyes
    Publication number: 20060128033
    Abstract: Fluorogenic or chromogenic dyes are useful as reporter molecules for detecting cell entry by a specific molecule.
    Type: Application
    Filed: January 30, 2006
    Publication date: June 15, 2006
    Applicant: Chiron Corporation
    Inventors: Daniel Suich, Ronald Zuckermann
  • Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor
    Publication number: 20060128947
    Abstract: Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 15, 2006
    Applicants: Chiron Corporation, G. D. Searle & Co.
    Inventors: Glenn Dorin, Bo Arve, Gregory Pattison, Robert Halenbeck, Kirk Johnson, Bao-Lu Chen, Rajsharan Rana, Maninder Hora, Hassan Madani, Michael Tsang, Mark Gustafson, Gary Bild, Gary Johnson
  • Protein complexes having factor VIII:C activity and production thereof
    Publication number: 20060122376
    Abstract: Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an .alpha.sub.1-antitrypsin signal sequence.
    Type: Application
    Filed: November 30, 2005
    Publication date: June 8, 2006
    Applicant: Chiron Corporation
    Inventors: Barbara Chapman, Rae Burke, Mirella Rasmussen, Jan Mikkelson
  • CpG receptor (CpG-R) and methods relating thereto
    Publication number: 20060121529
    Abstract: The present invention is directed to nucleic acid molecules and polypeptides encoding a CpG receptor (CpG-R). The CpG-R contains a THD, interacts with the MyD88 adapter protein, and may bind to CpG oligonucleotides. The present invention is also directed to antibodies against CpG-R and to methods of modulating an immune response and to methods of identifying compounds which bind to and/or modulate CpG-R.
    Type: Application
    Filed: February 8, 2006
    Publication date: June 8, 2006
    Applicant: Chiron Corporation
    Inventor: Mary Mackichan
  • Deamidated interferon-beta
    Publication number: 20060120998
    Abstract: Interferon-? protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-?, is deamidated exhibit a biological activity of native human interferon-? at an increased level and do not require HA for protein stabilization. The deamidated product is suitable for large scale manufacturing for incorporation in HA-containing or HA-free therapeutics for treatment of diseases including multiple sclerosis. An endoproteinase-C peptide map technique that produces a fingerprint profile for proteins using an enzymatic digest followed by RP-HPLC is also useful in quality control as an ID and/or quantitative test for the deamidated products.
    Type: Application
    Filed: November 10, 2005
    Publication date: June 8, 2006
    Applicant: Chiron Corporation
    Inventors: Kenji Furuya, Deborah Johnson-Jackson, Diana Ruscio
  • Multiple epitope fusion protein
    Patent number: 7056658
    Abstract: Multiple epitope fusion proteins and immunoassays using the same are disclosed. The multiple epitope fusion proteins are encompassed by the general structural formula (A)x?(B)y?C2 which represents a linear amino acid sequence, wherein B is an amino acid sequence of an epitope or cluster of epitopes and each B contains at least five and not more than 1,000 amino acids, y is an integer of 2 or more, A and C are each independently an amino acid sequence of an epitope or cluster of epitopes not adjacent to B in nature and x and z are each independently an integer of 0 or more wherein at least one of x and z is 1 or more.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: June 6, 2006
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, David Ying Chien
  • Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
    Patent number: 7056521
    Abstract: The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labile E. coli (LT).
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: June 6, 2006
    Assignee: Chiron Corporation
    Inventors: Gail Barchfeld, Giuseppe Del Giudice, Rino Rappuoli
  • Inhibitors of glycogen synthase 3 kinase
    Patent number: 7053097
    Abstract: Compounds of formula 1: wherein R1 is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0–3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro; R2 is hydroxy, amino, or lower alkoxy; R3 is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl; R4 is H or lower alkyl; and pharmaceutically acceptable salts and esters thereof; are effective inhibitors of GSK3.
    Type: Grant
    Filed: November 6, 2000
    Date of Patent: May 30, 2006
    Assignee: Chiron Corporation
    Inventors: Peter Schultz, David B. Ring, Stephen D. Harrison, Andrew M. Bray
  • Combination antiviral and interleukin-2 therapy for HIV infection
    Patent number: 7048924
    Abstract: Methods for promoting immunologic control of human immunodeficiency virus (HIV) in an HIV-infected subject are provided. The methods comprise administering to the subject highly active antiretroviral therapy (HAART) for at least one cycle of an intermittent dosing regimen in combination with administration of a pharmaceutical composition comprising a therapeutically effective amount of interleukin-2 (IL-2) or variant thereof. The combination of daily or intermittent administration of IL-2 (or variant thereof) and intermittent HAART promotes immunologic control of viral replication in the absence of HAART, thereby prolonging the length of time a patient may discontinue HAART before viral rebound necessitates further administration of HAART. Administration of IL-2 therapy in combination with an intermittent HAART dosing regimen provides an effective method for treating a subject infected with HIV.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: May 23, 2006
    Assignee: Chiron Corporation
    Inventor: David Sahner
  • Inhibitors of glycogen synthase kinase 3
    Patent number: 7045519
    Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: May 16, 2006
    Assignee: Chiron Corporation
    Inventors: John M. Nuss, Stephen D. Harrison, David B. Ring, Rustum S. Boyce, Kirk Johnson, Keith B. Pfister, Savithri Ramurthy, Lynn Seely, Allan S. Wagman, Manoj C. Desai, Barry H. Levine
  • Stabilized liquid polypeptide-containing pharmaceutical compositions
    Publication number: 20060093598
    Abstract: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.
    Type: Application
    Filed: December 5, 2005
    Publication date: May 4, 2006
    Applicant: Chiron Corporation
    Inventors: Bao-Lu Chen, Maninder Hora
  • Stabilized liquid polypeptide-containing pharmaceutical compositions
    Publication number: 20060093576
    Abstract: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.
    Type: Application
    Filed: December 5, 2005
    Publication date: May 4, 2006
    Applicant: Chiron Corporation
    Inventors: Bao-Lu Chen, Maninder Hora
  • Inhibitors of glycogen synthase kinase 3
    Patent number: 7037918
    Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: May 2, 2006
    Assignee: Chiron Corporation
    Inventors: John M. Nuss, Stephen D. Harrison, David B. Ring, Rustum S. Boyce, Sean P. Brown, Dane A. Goff, Kirk W. Johnson, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Lynn Seely, Sharadha Subramanian, Allan S. Wagman, Xiaohui A. Zhou
  • Inhibitors of glycogen synthase kinase 3
    Publication number: 20060089369
    Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Application
    Filed: September 6, 2005
    Publication date: April 27, 2006
    Applicant: Chiron Corporation
    Inventors: John Nuss, Stephen Harrison, David Ring, Rustum Boyce, Kirk Johnson, Keith Pfister, Savithri Ramurthy, Lynn Seely, Allan Wagman, Manoj Desai, Barry Levine
  • GSK3 polypeptides
    Publication number: 20060088932
    Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
    Type: Application
    Filed: December 10, 2003
    Publication date: April 27, 2006
    Applicant: Chiron Corporation
    Inventors: Stephen Harrison, John Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Fang, Doris Coit, Steve Nguyen, Angelica Medina-Selby
  • Substituted quinazolinone compounds
    Patent number: 7034033
    Abstract: A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure IA, IB, or IC where the values of the variable are defined herein.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: April 25, 2006
    Assignee: Chiron Corporation
    Inventors: Rustum S. Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Bryan Chang
  • Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
    Patent number: 7034009
    Abstract: The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases are provided, optionally in conjunction with other therapeutic agents.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: April 25, 2006
    Assignees: Sirna Therapeutics, Inc., Chiron Corporation
    Inventors: Pamela Pavco, James McSwiggen, Dan Stinchcomb, Jaime Escobedo